# Giles W Robinson

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 108 papers | 11,011 citations | 101384 36 h-index | 35952 97 g-index |
| 116 all docs | 116 docs citations | 116 times ranked | 13392 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Pretreatment Normal WM Magnetization Transfer Ratio Predicts Risk of Radiation Necrosis in Patients with Medulloblastoma. American Journal of Neuroradiology, 2022, 43, 299-303. | 1.2 | 1 |
| 2 | The posterior fossa syndrome questionnaire: using science to inform practice. Journal of Neuro-Oncology, 2022, , 1. | 1.4 | 0 |
| 3 | Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro-Oncology, 2022, 24, 1776-1789. | 0.6 | 37 |
| 4 | Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility. Laboratory Investigation, 2022, 102, 134-142. | 1.7 | 11 |
| 5 | Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. Neuro-Oncology, 2022, 24, 1166-1175. | 0.6 | 2 |
| 6 | Low-coverage whole-genome sequencing of cerebrospinal-fluid-derived cell-free DNA in brain tumor patients. STAR Protocols, 2022, 3, 101292. | 0.5 | 2 |
| 7 | MEDB-42. GermlineElp1 deficiency promotes genomic instability and survival of granule neuron progenitors primed for SHH medulloblastoma pathogenesis. Neuro-Oncology, 2022, 24, i115-i115. | 0.6 | 0 |
| 8 | EPCT-01. Pediatric Brain Tumor Consortium (PBTC)-055: A phase I study of trametinib and hydroxychloroquine (HCQ) for BRAF-fusion or Neurofibromatosis type-1 (NF1)-associated pediatric gliomas. Neuro-Oncology, 2022, 24, i35-i35. | 0.6 | 0 |
| 9 | MEDB-69. Clinical and molecular meta-analysis of three major medulloblastoma clinical trials (ACNS0331, SJMB03, ACNS0332) uncovers novel strategies to improve risk-stratified therapy. Neuro-Oncology, 2022, 24, i122-i122. | 0.6 | 1 |
| 10 | MEDB-29. Application of Rotterdam Post-Operative Cerebellar Mutism Syndrome Prediction Model to Patients Operated for Medulloblastoma in a Single Institution. Neuro-Oncology, 2022, 24, i111-i111. | 0.6 | 0 |
| 11 | INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.. Neuro-Oncology, 2022, 24, i188-i188. | 0.6 | 0 |
| 12 | MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 2022, 24, i124-i125. | 0.6 | 1 |
| 13 | LGG-22. SJ901: Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG). Neuro-Oncology, 2022, 24, i92-i92. | 0.6 | 2 |
| 14 | ATRT-22. Outcomes for children with recurrent atypical teratoid rhabdoid tumor: A single institution study with updated molecular and germline analysis. Neuro-Oncology, 2022, 24, i8-i8. | 0.6 | 1 |
| 15 | Primary cilia control translation and the cell cycle in medulloblastoma. Genes and Development, 2022, 36, 737-751. | 2.7 | 14 |
| 16 | Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial. Pediatric Blood and Cancer, 2021, 68, e28756. | 0.8 | 9 |
| 17 | Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial. Neuro-Oncology Advances, 2021, 3, vdaa168. | 0.4 | 6 |
| 18 | Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. Science Translational Medicine, 2021, 13, . | 5.8 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTCâ€042). Pediatric Blood and Cancer, 2021, 68, e28879. | 0.8 | 24 |
| 20 | Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. Acta Neuropathologica, 2021, 141, 771-785. | 3.9 | 44 |
| 21 | Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821. | 0.8 | 40 |
| 22 | Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Journal of Clinical Oncology, 2021, 39, 822-835. | 0.8 | 106 |
| 23 | Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clinical Cancer Research, 2021, 27, 2879-2889. | 3.2 | 35 |
| 24 | Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study. Neuro-Oncology, 2021, 23, 1586-1596. | 0.6 | 35 |
| 25 | Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. Cancer Discovery, 2021, 11, 3008-3027. | 7.7 | 88 |
| 26 | Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. Nature Communications, 2021, 12, 4089. | 5.8 | 27 |
| 27 | Abstract 642: Genomes for Kids: Comprehensive DNA and RNA sequencing defining the scope of actionable mutations in pediatric cancer. , 2021, , . | | 0 |
| 28 | Rare cases of medulloblastoma with hypermutation. Cancer Reports, 2021, , e1521. | 0.6 | 1 |
| 29 | Lorlatinib in a Child with ALK-Fusionâ€“Positive High-Grade Glioma. New England Journal of Medicine, 2021, 385, 761-763. | 13.9 | 27 |
| 30 | [11C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence. Journal of Nuclear Medicine, 2021, , jnumed.120.261891. | 2.8 | 4 |
| 31 | Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell, 2021, 39, 1519-1530.e4. | 7.7 | 64 |
| 32 | BIOM-36. SERIAL ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN MEDULLOBLASTOMA LIQUID BIOPSIES. Neuro-Oncology, 2021, 23, vi18-vi19. | 0.6 | 0 |
| 33 | Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma. Journal of Clinical Oncology, 2020, 38, 43-50. | 0.8 | 50 |
| 34 | Pharmacokinetic basis for dosing highâ€dose methotrexate in infants and young children with malignant brain tumours. British Journal of Clinical Pharmacology, 2020, 86, 362-371. | 1.1 | 17 |
| 35 | Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathologica, 2020, 139, 259-271. | 3.9 | 36 |
| 36 | Medulloblastomics revisited: biological and clinical insights from thousands of patients. Nature Reviews Cancer, 2020, 20, 42-56. | 12.8 | 147 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Childrenâ€™s Oncology Group (ACNS1221). Journal of Clinical Oncology, 2020, 38, 223-231. | 0.8 | 40 |
| 38 | Characterizing Posterior Fossa Syndrome: A Survey of Experts. Pediatric Neurology, 2020, 104, 19-22. | 1.0 | 15 |
| 39 | The RACE to Develop New Targeted Therapies for Children With CNS Tumors. Clinical Pharmacology and Therapeutics, 2020, 108, 434-436. | 2.3 | 3 |
| 40 | WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup?. Acta Neuropathologica, 2020, 140, 595-597. | 3.9 | 7 |
| 41 | Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. Acta Neuropathologica, 2020, 140, 209-225. | 3.9 | 45 |
| 42 | Exposureâ€“Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing. Clinical Cancer Research, 2020, 26, 1563-1573. | 3.2 | 14 |
| 43 | Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature, 2020, 580, 396-401. | 13.7 | 94 |
| 44 | Genomics Paves the Way for Better Infant Medulloblastoma Therapy. Journal of Clinical Oncology, 2020, 38, 2010-2013. | 0.8 | 14 |
| 45 | Food Is Love: Partnering With Families to Provide Nourishment at the End of Life. Journal of Clinical Oncology, 2020, 38, 1864-1867. | 0.8 | 3 |
| 46 | Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.. Journal of Clinical Oncology, 2020, 38, 10525-10525. | 0.8 | 24 |
| 47 | Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.. Journal of Clinical Oncology, 2020, 38, 107-107. | 0.8 | 15 |
| 48 | Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget, 2020, 11, 1942-1952. | 0.8 | 45 |
| 49 | Phase II study of alisertib as a single agent in recurrent or progressive atypical teratoid rhabdoid tumors.. Journal of Clinical Oncology, 2020, 38, 10542-10542. | 0.8 | 4 |
| 50 | Resolving medulloblastoma cellular architecture by single-cell genomics. Nature, 2019, 572, 74-79. | 13.7 | 273 |
| 51 | Evaluating pediatric spinal low-grade gliomas: a 30-year retrospective analysis. Journal of Neuro-Oncology, 2019, 145, 519-529. | 1.4 | 11 |
| 52 | Reply to â€˜Assembling the brain trust: the multidisciplinary imperative in neuro-oncologyâ€™. Nature Reviews Clinical Oncology, 2019, 16, 522-523. | 12.5 | 0 |
| 53 | Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathologica, 2019, 138, 309-326. | 3.9 | 180 |
| 54 | Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. Neuro-Oncology, 2019, 21, 1319-1330. | 0.6 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Challenges to curing primary brain tumours. Nature Reviews Clinical Oncology, 2019, 16, 509-520. | 12.5 | 540 |
| 56 | Medulloblastoma. Nature Reviews Disease Primers, 2019, 5, 11. | 18.1 | 376 |
| 57 | Computerized assessment of cognitive impairment among children undergoing radiation therapy for medulloblastoma. Journal of Neuro-Oncology, 2019, 141, 403-411. | 1.4 | 21 |
| 58 | Reoperation for Medulloblastoma Prior to Adjuvant Therapy. Neurosurgery, 2019, 84, 1050-1058. | 0.6 | 7 |
| 59 | Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.. Journal of Clinical Oncology, 2019, 37, 10009-10009. | 0.8 | 49 |
| 60 | Factors influencing the intracellular exposure of gemcitabine triphosphate in children with CNS tumors.. Journal of Clinical Oncology, 2019, 37, e13547-e13547. | 0.8 | 0 |
| 61 | Ovulation induction and oocyte retrieval for fertility preservation in young adolescents newly diagnosed with medulloblastoma: a case series. Journal of Obstetrics and Gynaecology, 2018, 38, 878-879. | 0.4 | 7 |
| 62 | Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases. Child's Nervous System, 2018, 34, 605-610. | 0.6 | 12 |
| 63 | DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474. | 13.7 | 1,872 |
| 64 | Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nature Communications, 2018, 9, 3962. | 5.8 | 142 |
| 65 | Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. Cancer, 2018, 124, 4168-4180. | 2.0 | 64 |
| 66 | Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncology, The, 2018, 19, 768-784. | 5.1 | 151 |
| 67 | FDGâ€“PET CT in the evaluation of primary and secondary pancreatic malignancies. Pediatric Blood and Cancer, 2018, 65, e27115. | 0.8 | 7 |
| 68 | Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798. | 5.1 | 268 |
| 69 | Outcomes for young children with molecularly defined ependymoma treated on the multi-institutional SJYC07 clinical trial.. Journal of Clinical Oncology, 2018, 36, 10548-10548. | 0.8 | 1 |
| 70 | A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clinical Cancer Research, 2017, 23, 2433-2441. | 3.2 | 134 |
| 71 | mTORC1-Mediated Inhibition of 4EBP1 Is Essential for Hedgehog Signaling-Driven Translation and Medulloblastoma. Developmental Cell, 2017, 43, 673-688.e5. | 3.1 | 48 |
| 72 | Non-Malignant Cerebrospinal Fluid Ascites in a Patient with Atypical Teratoid Rhabdoid Tumor. Oncology Research and Treatment, 2017, 40, 216-219. | 0.8 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies. Clinical Pharmacology and Therapeutics, 2017, 102, 752-753. | 2.3 | 5 |
| 74 | The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317. | 13.7 | 787 |
| 75 | ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of ageâ€"A report from the Children Oncology Group.. Journal of Clinical Oncology, 2017, 35, 10505-10505. | 0.8 | 7 |
| 76 | Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget, 2017, 8, 69295-69302. | 0.8 | 99 |
| 77 | Exploiting Laboratory Insights to Improve Outcomes of Pediatric Central Nervous System Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e540-e546. | 1.8 | 2 |
| 78 | Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 2016, 131, 821-831. | 3.9 | 478 |
| 79 | Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. Drug Metabolism and Disposition, 2016, 44, 1116-1122. | 1.7 | 15 |
| 80 | Preclinical studies of 5-fluoro-2â€²-deoxycytidine and tetrahydrouridine in pediatric brain tumors. Journal of Neuro-Oncology, 2016, 126, 225-234. | 1.4 | 11 |
| 81 | Exploiting Laboratory Insights to Improve Outcomes of Pediatric Central Nervous System Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e540-e546. | 1.8 | 1 |
| 82 | Zeb1 controls neuron differentiation and germinal zone exit by a mesenchymal-epithelial-like transition. ELife, 2016, 5, . | 2.8 | 60 |
| 83 | Dunn Index Bootstrap (DIBS): A procedure to empirically select a cluster analysis method that identifies biologically and clinically relevant molecular disease subgroups. BMC Bioinformatics, 2015, 16, P12. | 1.2 | 1 |
| 84 | Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations. Pediatric Blood and Cancer, 2015, 62, 1855-1858. | 0.8 | 6 |
| 85 | Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature Genetics, 2015, 47, 263-266. | 9.4 | 109 |
| 86 | Atypical teratoid/rhabdoid tumor (ATRT) arising from the 3rd cranial nerve in infants: a clinical-radiological entity?. Journal of Neuro-Oncology, 2015, 124, 175-183. | 1.4 | 12 |
| 87 | Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehogâ€"Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. Journal of Clinical Oncology, 2015, 33, 2646-2654. | 0.8 | 368 |
| 88 | Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation. International Journal of Radiation Oncology Biology Physics, 2015, 93, 47-53. | 0.4 | 14 |
| 89 | Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemotherapy and Pharmacology, 2015, 75, 27-35. | 1.1 | 25 |
| 90 | Developmental pharmacokinetics of topotecan (TPT), a renally excreted drug, in infants and young children with brain tumors.. Journal of Clinical Oncology, 2015, 33, 10055-10055. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma. Cancer Cell, 2014, 25, 516-529. | 7.7 | 128 |
| 92 | Concordance between the chang and the International Society of Pediatric Oncology (<scp>SIOP</scp>) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatric Blood and Cancer, 2014, 61, 601-605. | 0.8 | 36 |
| 93 | Medulloblastomaâ€"translating discoveries from the bench to the bedside. Nature Reviews Clinical Oncology, 2014, 11, 714-722. | 12.5 | 145 |
| 94 | Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer, 2014, 14, 258. | 1.1 | 162 |
| 95 | Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature, 2014, 511, 428-434. | 13.7 | 520 |
| 96 | The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin-Induced Ototoxicity in Children With Cancer. Clinical Pharmacology and Therapeutics, 2013, 94, 252-259. | 2.3 | 80 |
| 97 | Impact of tumor location on medulloblastoma subtyping and treatment (Commentary on teo et al.,) Tj ETQq1 1 0.784314 rgBT /Over | 0.8 | 9 |
| 98 | Role of MYC in Medulloblastoma. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a014308-a014308. | 2.9 | 123 |
| 99 | Medulloblastomics: the end of the beginning. Nature Reviews Cancer, 2012, 12, 818-834. | 12.8 | 560 |
| 100 | Novel mutations target distinct subgroups of medulloblastoma. Nature, 2012, 488, 43-48. | 13.7 | 742 |
| 101 | A Mouse Model of the Most Aggressive Subgroup of Human Medulloblastoma. Cancer Cell, 2012, 21, 168-180. | 7.7 | 250 |
| 102 | Developmental origins of neural tumours: old idea, new approaches. Neuropathology and Applied Neurobiology, 2012, 38, 222-227. | 1.8 | 3 |
| 103 | Abstract 1434: A mouse model of the most aggressive subgroup of human medulloblastoma. , 2012, , . | | 0 |
| 104 | Use of whole genome sequencing to identify novel mutations in distinct subgroups of medulloblastoma.. Journal of Clinical Oncology, 2012, 30, 9518-9518. | 0.8 | 0 |
| 105 | Medulloblastoma: advances and challenges. F1000 Biology Reports, 2011, 3, 5. | 4.0 | 9 |
| 106 | Abstract 3448: Subtypes of medulloblastoma have distinct developmental origins. , 2011, , . | | 1 |
| 107 | Subtypes of medulloblastoma have distinct developmental origins. Nature, 2010, 468, 1095-1099. | 13.7 | 710 |
| 108 | Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. Neuro-Oncology, 0, , . | 0.6 | 7 |